|
1.
|
Adler DJ and Korelitz BI: The therapeutic
efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J
Gastroenterol. 85:717–722. 1990.PubMed/NCBI
|
|
2.
|
Sandborn W, Sutherland L, Pearson D, May
G, Modigliani R and Prantera C: Azathioprine or 6-mercaptopurine
for inducing remission of Crohn’s disease. Cochrane Database Syst
Rev. 6:CD0005452000.
|
|
3.
|
Hibi T and Ogata H: Novel
pathophysiological concepts of inflammatory bowel disease. J
Gastroenterol. 41:10–16. 2006. View Article : Google Scholar
|
|
4.
|
Gearry RB, Barclay ML, Burt MJ, Collett JA
and Chapman BA: Thiopurine drug adverse effects in a population of
New Zealand patients with inflammatory bowel disease.
Pharmacoepidemiol Drug Saf. 13:563–567. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Van Dieren JM, Hansen BE, Kuipers EJ,
Nieuwenhuis EE and Van der Woude CJ: Meta-analysis: inosine
triphosphate pyrophosphatase polymorphisms and thiopurine toxicity
in the treatment of inflammatory bowel disease. Aliment Pharmacol
Ther. 26:643–652. 2007.
|
|
6.
|
Gisbert JP and Gomollon F:
Thiopurine-induced myelotoxicity in patients with inflammatory
bowel disease: a review. Am J Gastroenterol. 103:1783–1800. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Takatsu N, Matsui T, Murakami Y, et al:
Adverse reactions to azathioprine cannot be predicted by thiopurine
S-methyltransferase genotype in Japanese patients with inflammatory
bowel disease. J Gastroenterol Hepatol. 24:1258–1264. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Lees CW, Maan AK, Hansoti B, Satsangi J
and Arnott ID: Tolerability and safety of mercaptopurine in
azathioprine-intolerant patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 27:220–227. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Winter JW, Gaffney D, Shapiro D, et al:
Assessment of thiopurine methyltransferase enzyme activity is
superior to genotype in predicting myelosuppression following
azathioprine therapy in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 25:1069–1077. 2007. View Article : Google Scholar
|
|
10.
|
Lichtenstein GR, Sbreu MT, Cohen R and
Tremaine W: American Gastroenterological Association Institute
technical review on corticosteroids, immunomodulators, and
infliximab in inflammatory bowel disease. Rev Gastroenterol Mex.
71:351–401. 2006.(In Spanish).
|
|
11.
|
Hibi T, Naganuma M, Kitahora T, Kinjyo F
and Shimoyama T: Low-dose azathioprine is effective and safe for
maintenance of remission in patients with ulcerative colitis. J
Gastroenterol. 38:740–746. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Derijks LJ, Gilissen LP, Engels LG, et al:
Pharmacokinetics of 6-thioguanine in patients with inflammatory
bowel disease. Ther Drug Monit. 28:45–50. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Haglund S, Taipalensuu J, Peterson C and
Almer S: IMPDH activity in thiopurine-treated patients with
inflammatory bowel disease – relation to TPMT activity and
metabolite concentrations. Br J Clin Pharmacol. 65:69–77.
2007.PubMed/NCBI
|
|
14.
|
Ban H, Andoh A, Tanaka A, et al: Analysis
of thiopurine S-methyltransferase genotypes in Japanese patients
with inflammatory bowel disease. Intern Med. 47:1645–1648. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Hiratsuka M, Inoue T, Omori F, Agatsuma Y
and Mizugaki M: Genetic analysis of thiopurine methyltransferase
polymorphism in a Japanese population. Mutat Res. 448:91–95. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Uchiyama K, Nakamura M, Kubota T, Yamane
T, Fujise K and Tajiri H: Thiopurine S-methyltransferase and
inosine triphosphate pyrophosphohydrolase genes in Japanese
patients with inflammatory bowel disease in whom adverse drug
reactions were induced by azathioprine/6-mercaptopurine treatment.
J Gastroenterol. 44:197–203. 2009. View Article : Google Scholar
|
|
17.
|
Kurzawski M, Dziewanowski K, Lener A and
Drozdzik M: TPMT but not ITPA gene polymorphism influences the risk
of azathioprine intolerance in renal transplant recipients. Eur J
Clin Pharmacol. 65:533–540. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Allorge D, Hamdan R, Broly F, Libersa C
and Colombel JF: ITPA genotyping test does not improve detection of
Crohn’s disease patients at risk of azathioprine/6-mercaptopurine
induced myelosuppression. Gut. 54:5652005.
|
|
19.
|
Zelinkova Z, Derijks LJ, Stokkers PC, et
al: Inosine triphosphate pyrophosphatase and thiopurine
s-methyltransferase genotypes relationship to azathioprine-induced
myelosuppression. Clin Gastroenterol Hepatol. 4:44–49. 2006.
View Article : Google Scholar
|
|
20.
|
Wielinga PR, Reid G, Challa EE, et al:
Thiopurine metabolism and identification of the thiopurine
metabolites transported by MRP4 and MRP5 overexpressed in human
embryonic kidney cells. Mol Pharmacol. 62:1321–1331. 2002.
View Article : Google Scholar
|
|
21.
|
Krishnamurthy P, Schwab M, Takenaka K, et
al: Transporter-mediated protection against thiopurine-induced
hematopoietic toxicity. Cancer Res. 68:4983–4989. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Peng XX, Shi Z, Damaraju VL, et al:
Up-regulation of MRP4 and down-regulation of influx transporters in
human leukemic cells with acquired resistance to 6-mercaptopurine.
Leuk Res. 32:799–809. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Borst P, Evers R, Kool M and Wijnholds J:
A family of drug transporters: the multidrug resistance-associated
proteins. J Natl Cancer Inst. 92:1295–1302. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Ban H, Andoh A, Imaeda H, et al: The
multidrug-resistance protein 4 polymorphism is a new factor
accounting for thiopurine sensitivity in Japanese patients with
inflammatory bowel disease. J Gastroenterol. 45:1014–1021. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Yates CR, Krynetski EY, Loennechen T, et
al: Molecular diagnosis of thiopurine S-methyltransferase
deficiency: genetic basis for azathioprine and mercaptopurine
intolerance. Ann Intern Med. 126:608–614. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Marinaki AM, Ansari A, Duley JA, et al:
Adverse drug reactions to azathioprine therapy are associated with
polymorphism in the gene encoding inosine triphosphate
pyrophosphatase (ITPase). Pharmacogenetics. 14:181–187. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Hui L, DelMonte T and Ranade K: Genotyping
using the TaqMan assay. Current Protocols Human Genetics. Haines
JL: John Wiley; New York: 2008, View Article : Google Scholar
|
|
28.
|
Mitani Y, Lezhava A, Sakurai A, et al:
Rapid and cost-effective SNP detection method: application of
SmartAmp2 to pharmaco-genomics research. Pharmacogenomics.
10:1187–1197. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Morita A, Nakayama T, Doba N, Hinohara S,
Mizutani T and Soma M: Genotyping of triallelic SNPs using TaqMan
PCR. Mol Cell Probes. 21:171–176. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Livak KJ: Allelic discrimination using
fluorogenic probes and the 5′ nuclease assay. Genet Anal.
14:143–149. 1999.
|
